While reductions in Kir4.1 may occur secondary to changes in the BBB due to increase in Aβ deposition, such reductions in expression may play a role in overall disease progression as well as the development of co-morbidities such as seizures [217] in AD patients. This evidence concerns the gene KCNJ10 and Alzheimer disease.